NCT00168909View on ClinicalTrials.gov

Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

May 31, 2008

Conditions
Osteoporosis, PostmenopausalOsteopeniaFalls
Interventions
DRUG

alfacalcidol

alfacalcidol 1 µg once daily, oral, for 3 years

DRUG

placebo

placebo once daily, oral, for 3 years

Trial Locations (2)

12200

Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin

73732

Centre for Muscle and Bone Research, Aerpah-Kliniken Esslingen, Stuttgart

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT00168909 - Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study) | Biotech Hunter | Biotech Hunter